| Dr Suzanne Yvette Succop, MD | |
|
200 Knuth Rd, Suite 150, Boynton Beach, FL 33436-4629 | |
| (561) 738-7007 | |
| (561) 738-7421 |
| Full Name | Dr Suzanne Yvette Succop |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 34 Years |
| Location | 200 Knuth Rd, Boynton Beach, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578583076 | NPI | - | NPPES |
| 378265400 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | ME62069 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midway Specialty Care Center Inc | 9638306087 | 21 |
News Archive
A UC Irvine researcher has found a novel tumor- suppressor function for a gene that, when mutated, often triggers breast cancer in women.
Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 2 days ago
| Entity Name | Id Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134217987 PECOS PAC ID: 5991602963 Enrollment ID: O20040129000161 |
News Archive
A UC Irvine researcher has found a novel tumor- suppressor function for a gene that, when mutated, often triggers breast cancer in women.
Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 2 days ago
| Entity Name | Midway Specialty Care Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376970814 PECOS PAC ID: 9638306087 Enrollment ID: O20131211000645 |
News Archive
A UC Irvine researcher has found a novel tumor- suppressor function for a gene that, when mutated, often triggers breast cancer in women.
Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suzanne Yvette Succop, MD 3245 Equestrian Dr, Boca Raton, FL 33434-3361 Ph: (561) 738-7007 | Dr Suzanne Yvette Succop, MD 200 Knuth Rd, Suite 150, Boynton Beach, FL 33436-4629 Ph: (561) 738-7007 |
News Archive
A UC Irvine researcher has found a novel tumor- suppressor function for a gene that, when mutated, often triggers breast cancer in women.
Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.
NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Commission has granted orphan drug designation to Natpara (recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of hypoparathyroidism.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 2 days ago
Dr. Jonathan Michael Greer, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6056 Boynton Beach Blvd Ste 145, Boynton Beach, FL 33437 Phone: 561-439-1800 Fax: 561-439-4874 | |
Sheeba Jacob, ARNP Infectious Disease Medicare: Medicare Enrolled Practice Location: 2300 S Congress Ave Ste 100, Boynton Beach, FL 33426 Phone: 561-735-7531 Fax: 561-572-0384 | |
Rogelio A Brito, D.O. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 2623 S Seacrest Blvd, Suite 216, Boynton Beach, FL 33435 Phone: 561-742-0065 Fax: 561-742-0105 | |
Dr. Kenneth Lee, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1501 Corporate Dr # Way-240, Boynton Beach, FL 33426 Phone: 561-736-8806 Fax: 561-736-3384 | |
Mr. Sunket Ahkee, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2300 South Congress Ave Ste 100, Boynton Beach, FL 33426 Phone: 561-735-7531 Fax: 561-742-8250 | |
Om Prakash Singh, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2828 S Seacrest Blvd Ste 101, Boynton Beach, FL 33435 Phone: 561-736-1070 Fax: 561-738-5721 | |
Mr. Lawrence H Port, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 8645 W Boynton Beach Blvd, Boynton Beach, FL 33472 Phone: 561-853-1621 |